Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Monopar Therapeutics changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 11 | 8 | −3 |
| Shares | 231.6K | 192.4K | −39.2K (−16.9%) |
| Value | $322.9K | $164.5K | −$158.4K (−49.0%) |
New holders (2)
Institutions that held Monopar Therapeutics at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 32,761 | $28.0K | 0.00% |
| FMR LLC | 150 | $128 | 0.00% |
Sold out (5)
Institutions that held Monopar Therapeutics at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Northern Trust Corp | 37,051 | $51.5K |
| Kestra Private Wealth Services, LLC | 23,455 | $32.6K |
| UBS Group AG | 6,388 | $8.88K |
| Royal Bank of Canada | 5,000 | $7.00K |
| JPMorgan Chase & Co | 2,414 | $3.00K |